G
GVK Biosciences
Home | GVK BIO | CRDO | Beyond Contract Research Organization
About GVK Biosciences
GVK Biosciences, now rebranded as Aragen Life Sciences, is a global contract research, development, and manufacturing organization (CRDMO) established in 2001. Initially founded by Gunupati Venkata Krishna Reddy as part of the GVK Group, a diversified Indian conglomerate, the company began its journey with an informatics division. A significant milestone occurred in 2004 with the entry of D.S. Brar, former CEO of Ranbaxy Laboratories, as promoter and chairman, steering the company's focus on the life sciences R&D value chain. In 2021, coinciding with its 20th anniversary and an investment from Goldman Sachs, GVK BIO rebranded to Aragen Life Sciences to better position itself as a global solutions partner for the biopharma industry.
The company operates on a fee-for-service and full-time equivalent (FTE) based business model, providing integrated services to a diverse client base of over 450 companies that includes large pharmaceutical corporations, biotechnology firms, agrochemical companies, and animal health organizations. With a significant portion of its revenue derived from clients in the US and Europe, Aragen functions as a key partner in the drug development lifecycle. Its business is structured to assist clients in bringing their products to market more efficiently by offering solutions across both small and large molecule platforms. This dual capability was significantly enhanced by the 2014 acquisition of Aragen Bioscience, a US-based preclinical CRO specializing in large-molecule biologics services.
Aragen provides a comprehensive suite of services spanning the entire drug development continuum. This includes early-stage discovery services like medicinal chemistry and biologics, which constituted approximately 65% of its revenue in fiscal 2023. The company also offers development and manufacturing services for drug substances, process research and development, and formulation development. A notable offering is its informatics division, which provides proprietary bio/chemical databases like GOSTAR and IT solutions for data management and analytics to accelerate drug discovery. With a global team of over 4,000, including more than 400 PhDs, Aragen operates across multiple sites in India and the United States, positioning itself as a strategic partner for advancing healthcare solutions from concept to commercialization.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 1,575
- Open positions
- None listed
- Dealroom signal
- 27.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Analytics, Biotechnology, Biotech and Pharma, Hard Tech
- Business model
- Manufacturing
- Client focus
- B2B
- Investment activity
- 2 companies, latest Nov 2014
- Capital deployed
- —
- Preferred round
- ACQUISITION
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SECONDARYOther financing | May 2021 | $0 | — | Undisclosed | — |
| SECONDARYOther financing | Dec 2015 | $25M | — | Chrys Capital | — |
Growth signals
Latest recorded traffic for GVK Biosciences is 320 monthly website visits, up 60% over the last three months. GVK Biosciences's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Vanta BioscienceGummidipoondi, IndiaFull service preclinical contract research organization with research laboratories in chennai, india
→
Aragen BioscienceMorgan Hill, United StatesPreclinical contract research and development services the company specializes in recombinant cell line
→
GVK Biosciences in its local ecosystem
The GVK Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
Sequoia
Chrys Capital
Other known investors1 additional known investor
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about GVK Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See GVK Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










